Brief: Verrica Pharmaceuticals Receives Positive Feedback From The European Medicines Agency (EMA) Supporting A Clear Regulatory Path Forward To File For Approval Of Ycanth® In The European Union
20/10/2025 21:29
Oct 20 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O: VERRICA PHARMACEUTICALS RECEIVES POSITIVE FEEDBACK FROM THE EUROPEAN MEDICINES AGENCY (EMA) SUPPORTING A CLEAR REGULATORY PATH FORWARD TO FILE FOR APPROVAL OF YCANTH® IN THE EUROPEAN UNION VERRICA PHARMACEUTICALS INC - PLANS REGULATORY SUBMISSION FOR YCANTH BY Q4 2026 Source text: ID:nGNX68WDYR Further company coverage: VRCA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data